Compare Stocks: NXL, NMTC, IRIX, and NDRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRIX IRIDEX	$0.64 +1.8%	$0.74	$0.61 ▼ $1.65	$11.30M	0.67	50,734 shs	24,332 shs
NDRA ENDRA Life Sciences	$6.06 +3.1%	$5.22	$2.96 ▼ $9.85	$9.09M	-0.09	40,374 shs	39,742 shs
NMTC NeuroOne Medical Technologies	$1.12 +13.7%	$1.62	$0.96 ▼ $6.96	$10.20M	0.77	132,963 shs	197,383 shs
NXL Nexalin Technology	$5.73 -24.1%	$7.63	$4.00 ▼ $60.00	$4.20M	4.08	3.13 million shs	1.35 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRIX IRIDEX	+1.77%	+2.91%	-10.67%	-43.08%	-43.08%
NDRA ENDRA Life Sciences	+3.06%	+0.33%	-6.19%	+28.39%	+7.83%
NMTC NeuroOne Medical Technologies	+13.69%	-15.79%	-32.93%	-62.67%	-79.01%
NXL Nexalin Technology	-24.11%	+26.49%	-7.43%	-47.09%	-78.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRIX IRIDEX	$0.64 +1.8%	$0.74	$0.61 ▼ $1.65	$11.30M	0.67	50,734 shs	24,332 shs
NDRA ENDRA Life Sciences	$6.06 +3.1%	$5.22	$2.96 ▼ $9.85	$9.09M	-0.09	40,374 shs	39,742 shs
NMTC NeuroOne Medical Technologies	$1.12 +13.7%	$1.62	$0.96 ▼ $6.96	$10.20M	0.77	132,963 shs	197,383 shs
NXL Nexalin Technology	$5.73 -24.1%	$7.63	$4.00 ▼ $60.00	$4.20M	4.08	3.13 million shs	1.35 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRIX IRIDEX	+1.77%	+2.91%	-10.67%	-43.08%	-43.08%
NDRA ENDRA Life Sciences	+3.06%	+0.33%	-6.19%	+28.39%	+7.83%
NMTC NeuroOne Medical Technologies	+13.69%	-15.79%	-32.93%	-62.67%	-79.01%
NXL Nexalin Technology	-24.11%	+26.49%	-7.43%	-47.09%	-78.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRIX IRIDEX	2.00	Hold	$3.00	366.42% Upside
NDRA ENDRA Life Sciences	2.00	Hold	$25.00	312.54% Upside
NMTC NeuroOne Medical Technologies	2.40	Hold	$7.33	554.76% Upside
NXL Nexalin Technology	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest NXL, NMTC, IRIX, and NDRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	NXL Nexalin Technology	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/28/2026	NDRA ENDRA Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/25/2026	NXL Nexalin Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/18/2026	IRIX IRIDEX	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	NDRA ENDRA Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	NXL Nexalin Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/4/2026	IRIX IRIDEX	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	IRIX IRIDEX	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	NMTC NeuroOne Medical Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/18/2026	NXL Nexalin Technology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/14/2026	NMTC NeuroOne Medical Technologies	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$13.00 ➝ $5.00

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRIX IRIDEX	$52.67M	0.21	N/A	N/A	($0.06) per share	-10.72
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	$1.92 per share	N/A
NMTC NeuroOne Medical Technologies	$12.10M	0.84	N/A	N/A	$0.85 per share	1.32
NXL Nexalin Technology	$300K	13.94	N/A	N/A	$6.03 per share	0.95

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRIX IRIDEX	-$4.44M	-$0.20	N/A	N/A	N/A	-6.88%	N/A	-12.55%	11/17/2026 (Estimated)
NDRA ENDRA Life Sciences	-$7.03M	-$6.38	N/A	N/A	N/A	N/A	-246.34%	-150.81%	11/13/2026 (Estimated)
NMTC NeuroOne Medical Technologies	-$3.61M	-$0.95	N/A	N/A	N/A	-71.50%	-128.12%	-86.34%	12/15/2026 (Estimated)
NXL Nexalin Technology	-$8.22M	-$14.41	N/A	N/A	N/A	-4,141.94%	-278.24%	-218.42%	12/2/2026 (Estimated)

Latest NXL, NMTC, IRIX, and NDRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IRIX IRIDEX	-$0.01	-$0.07	-$0.06	-$0.07	$13.59 million	$12.57 million
8/14/2026	Q2 2026	NDRA ENDRA Life Sciences	-$0.84	-$0.63	+$0.21	$0.06	$0.10 million	N/A
8/13/2026	Q3 2026	NMTC NeuroOne Medical Technologies	-$0.21	-$0.28	-$0.07	-$0.28	$2.17 million	$1.97 million
8/12/2026	Q2 2026	NXL Nexalin Technology	-$3.00	-$0.11	+$2.89	-$3.30	$0.09 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRIX IRIDEX	N/A	N/A	N/A	N/A	N/A
NDRA ENDRA Life Sciences	N/A	N/A	N/A	N/A	N/A
NMTC NeuroOne Medical Technologies	N/A	N/A	N/A	N/A	N/A
NXL Nexalin Technology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRIX IRIDEX	N/A	1.82	1.08
NDRA ENDRA Life Sciences	N/A	7.10	7.10
NMTC NeuroOne Medical Technologies	N/A	2.84	1.71
NXL Nexalin Technology	N/A	1.25	1.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRIX IRIDEX	20.10%
NDRA ENDRA Life Sciences	1.19%
NMTC NeuroOne Medical Technologies	16.07%
NXL Nexalin Technology	0.65%

Insider Ownership

Company	Insider Ownership
IRIX IRIDEX	8.60%
NDRA ENDRA Life Sciences	10.00%
NMTC NeuroOne Medical Technologies	11.80%
NXL Nexalin Technology	16.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRIX IRIDEX	108	17.57 million	16.05 million	Optionable
NDRA ENDRA Life Sciences	11	1.50 million	1.35 million	Not Optionable
NMTC NeuroOne Medical Technologies	18	9.11 million	8.03 million	Optionable
NXL Nexalin Technology	8	730,000	610,000	Not Optionable

NXL, NMTC, IRIX, and NDRA Headlines

Recent News About These Companies

Zacks Research Upgrades Nexalin Technology (NASDAQ:NXL) to Hold

October 3 at 6:03 AM | americanbankingnews.com

What is Maxim Group's Forecast for NXL Q3 Earnings?

October 2 at 7:13 AM | americanbankingnews.com

Nexalin Regains Nasdaq Compliance Amid Ongoing Listing Risks

October 1 at 6:30 PM | tipranks.com

Nexalin Signs South America Neurostimulation Distribution Agreement

October 1 at 6:30 PM | tipranks.com

These Stocks Roar into October with Fresh Catalysts

October 1 at 1:14 PM | markets.businessinsider.com

Nexalin Technology signs South America distribution agreement for Nexalin Sync commercialization

October 1 at 1:14 PM | msn.com

Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward ...

October 1 at 1:14 PM | finance.yahoo.com

Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation

October 1 at 8:30 AM | globenewswire.com

Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy

September 29, 2026 | globenewswire.com

Head-To-Head Contrast: Nexalin Technology (NASDAQ:NXL) & Fresenius SE & Co. (OTCMKTS:FSNUY)

September 29, 2026 | americanbankingnews.com

Nexalin Technology Granted Conditional Nasdaq Listing Extension

September 28, 2026 | tipranks.com

Comparing DENTSPLY SIRONA (NASDAQ:XRAY) & Nexalin Technology (NASDAQ:NXL)

September 27, 2026 | americanbankingnews.com

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language ...

September 3, 2026 | markets.businessinsider.com

Nexalin Reports New Cognitive Improvements In Alzheimer's Analysis, Plans U.S. Pilot Study

September 3, 2026 | rttnews.com

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study

September 3, 2026 | globenewswire.com

Nexalin Technology Announces Key Executive Leadership Departure

September 2, 2026 | tipranks.com

Nexalin Technology, Inc.: Nexalin Technology Announces Reverse Stock Split

August 27, 2026 | finanznachrichten.de

Nexalin Technology Announces 1-for-30 Reverse Stock Split to Maintain Nasdaq Compliance

August 27, 2026 | quiverquant.comQ

Nexalin Technology Announces Reverse Stock Split

August 27, 2026 | globenewswire.com

Nexalin Technology Raises Liquidity via Short-Term Note

August 21, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL, NMTC, IRIX, and NDRA Company Descriptions

IRIDEX NASDAQ:IRIX

$0.64 +0.01 (+1.77%)

Closing price 10/2/2026 03:49 PM Eastern

Extended Trading

$0.63 -0.01 (-1.43%)

As of 10/2/2026 04:49 PM Eastern

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

ENDRA Life Sciences NASDAQ:NDRA

$6.06 +0.18 (+3.06%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$6.13 +0.07 (+1.09%)

As of 10/2/2026 07:57 PM Eastern

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

NeuroOne Medical Technologies NASDAQ:NMTC

$1.12 +0.13 (+13.69%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.11 -0.01 (-0.89%)

As of 10/2/2026 07:59 PM Eastern

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

Nexalin Technology NASDAQ:NXL

$5.73 -1.82 (-24.11%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$5.48 -0.25 (-4.31%)

As of 10/2/2026 08:00 PM Eastern

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NXL, NMTC, IRIX, and NDRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NXL, NMTC, IRIX, and NDRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NXL, NMTC, IRIX, and NDRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL, NMTC, IRIX, and NDRA Company Descriptions

IRIDEX NASDAQ:IRIX

ENDRA Life Sciences NASDAQ:NDRA

NeuroOne Medical Technologies NASDAQ:NMTC

Nexalin Technology NASDAQ:NXL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NXL, NMTC, IRIX, and NDRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NXL, NMTC, IRIX, and NDRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NXL, NMTC, IRIX, and NDRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NXL, NMTC, IRIX, and NDRA Company Descriptions

IRIDEX NASDAQ:IRIX

ENDRA Life Sciences NASDAQ:NDRA

NeuroOne Medical Technologies NASDAQ:NMTC

Nexalin Technology NASDAQ:NXL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools